Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Tomás JF[au]:

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Salar A et al. Blood. (2017)

An experience in integrated management of clinical risks. Fernández-Castelló AI et al. J Healthc Qual Res. (2018)

Reducing Physical Restraints in Nursing Homes: A Report From Maria Wolff and Sanitas. Muñiz R et al. J Am Med Dir Assoc. (2016)

Search results

Items: 1 to 50 of 102

1.

Comparing Three Methods for Reducing Psychotropic Use in Older Demented Spanish Care Home Residents.

Weeks WB, Mishra MK, Curto D, Petersen CL, Cano P, Hswen Y, Serra SV, Elwyn G, Godfrey MM, Soro PS, Tomás JF.

J Am Geriatr Soc. 2019 Jul;67(7):1444-1453. doi: 10.1111/jgs.15855. Epub 2019 Mar 8.

PMID:
30848834
2.

An experience in integrated management of clinical risks.

Fernández-Castelló AI, Valle-Pérez P, Pagonessa-Damonte ML, Blazquez-Muñoz M, Tomás JF.

J Healthc Qual Res. 2018 Nov - Dec;33(6):311-318. doi: 10.1016/j.jhqr.2018.09.002. Epub 2018 Nov 27.

PMID:
30501942
3.

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.

Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver J, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C.

Blood. 2017 Oct 12;130(15):1772-1774. doi: 10.1182/blood-2017-07-795302. Epub 2017 Aug 11. No abstract available.

PMID:
28801448
4.

Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.

González-Barca E, Canales MA, Salar A, Ferrer S, Domingo-Domenech E, Vidal MJ, Grande C, Bargay J, Gardella S, Oriol A, Briones J, García-Frade J, Bello JL, Sánchez-Blanco JJ, Peñalver FJ, Tomás JF, Asensio A, López A, Caballero D; GELTAMO Group (Grupo Español de Linfoma y Trasplante de Médula Ósea).

Acta Haematol. 2016;136(2):76-84. doi: 10.1159/000444625. Epub 2016 May 18.

PMID:
27188649
5.

Reducing Physical Restraints in Nursing Homes: A Report From Maria Wolff and Sanitas.

Muñiz R, Gómez S, Curto D, Hernández R, Marco B, García P, Tomás JF, Olazarán J.

J Am Med Dir Assoc. 2016 Jul 1;17(7):633-9. doi: 10.1016/j.jamda.2016.03.011. Epub 2016 May 6.

6.

Recombinant pre-miR-29b for Alzheimer´s disease therapeutics.

Pereira PA, Tomás JF, Queiroz JA, Figueiras AR, Sousa F.

Sci Rep. 2016 Jan 28;6:19946. doi: 10.1038/srep19946.

7.

CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma.

Martín-Moreno AM, Roncador G, Maestre L, Mata E, Jiménez S, Martínez-Torrecuadrada JL, Reyes-García AI, Rubio C, Tomás JF, Estévez M, Pulford K, Piris MA, García JF.

PLoS One. 2015 Jun 12;10(6):e0125203. doi: 10.1371/journal.pone.0125203. eCollection 2015.

8.

First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial.

Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver FJ, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C; Grupo Español de Linfomas/Trasplante de Médula Ósea (GELTAMO).

Lancet Haematol. 2014 Dec;1(3):e104-11. doi: 10.1016/S2352-3026(14)00021-0. Epub 2014 Nov 19.

PMID:
27029228
9.

Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.

Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D; Grupo Español de Linfomas y Trasplante Autologo de Médula Ósea (GELTAMO).

Haematologica. 2014 Jul;99(7):e126. doi: 10.3324/haematol.2014.108308. No abstract available.

10.

Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.

Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D; GELTAMO.

Haematologica. 2014 Mar;99(3):505-10. doi: 10.3324/haematol.2013.093450. Epub 2013 Oct 25.

11.

Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.

González-Barca E, Canales M, Cortés M, Vidal MJ, Salar A, Oriol A, Bargay J, Bello JL, Sánchez JJ, Tomás JF, Donato E, Ferrer S, Caballero D; GELTAMO (Grupo Español de Linfoma y Trasplante de Médula Ósea).

Nucl Med Commun. 2013 Oct;34(10):946-52. doi: 10.1097/MNM.0b013e328363c695.

PMID:
23880897
12.

Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination.

Rojas R, Molina JR, Jarque I, Montes C, Serrano J, Sanz J, Besalduch J, Carreras E, Tomas JF, Madero L, Rubio D, Conde E, Sanz MA, Torres A.

Mediterr J Hematol Infect Dis. 2012;4(1):e2012011. doi: 10.4084/MJHID.2012.011. Epub 2012 Feb 10.

13.

Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series.

Guisado-Vasco P, Arranz-Saez R, Canales M, Cánovas A, Garcia-Laraña J, García-Sanz R, Lopez A, López JL, Llanos M, Moraleda JM, Rodriguez J, Rayón C, Sabin P, Salar A, Marín-Niebla A, Morente M, Sánchez-Godoy P, Tomás JF, Muriel A, Abraira V, Piris MA, Garcia JF, Montalban C; Spanish Hodgkin Lymphoma Study Group.

Leuk Lymphoma. 2012 May;53(5):812-9. doi: 10.3109/10428194.2011.635861. Epub 2012 Jan 31.

PMID:
22185637
14.

POEMS syndrome with severe neurological damage clinically recovered with lenalidomide.

Tomás JF, Giraldo P, Lecumberri R, Nistal S.

Haematologica. 2012 Feb;97(2):320-2. doi: 10.3324/haematol.2011.041897. Epub 2011 Nov 4. No abstract available.

15.

The challenge of recurrent follicular lymphoma.

Tomás JF.

Lancet Oncol. 2011 Aug;12(8):714-6. doi: 10.1016/S1470-2045(11)70181-4. Epub 2011 Jul 1. No abstract available.

PMID:
21724461
16.

Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).

Tomás JF, Montalbán C, De Sevilla AF, Martínez-López J, Díaz N, Canales M, Martínez R, Sánchez-Godoy P, Caballero MD, Peñalver J, Prieto E, Salar A, Burgaleta C, Queizán JA, Bajo R, De Oña R, De La Serna J.

Leuk Lymphoma. 2011 Mar;52(3):409-16. doi: 10.3109/10428194.2010.543717. Epub 2011 Jan 28.

PMID:
21275633
17.

Long-Term Results of Fludarabine/Melphalan as a Reduced-Intensity Conditioning Regimen in Mantle Cell Lymphoma: The GELTAMO Experience.

Cruz JG, Martino R, Balsalobre P, Heras I, Piñana JL, Serrano D, de la Serna J, Tomás JF, Díez-Martíin JL, Caballero D.

Ther Adv Hematol. 2011 Feb;2(1):5-10. doi: 10.1177/2040620710396752.

18.

Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.

Rivero A, Rapado I, Tomás JF, Montalbán C, de Oña R, Paz-Carreira J, Canales M, Martínez R, Sánchez-Godoy P, de Sevilla AF, de la Serna J, Martínez-López J.

Leuk Res. 2011 Apr;35(4):431-7. doi: 10.1016/j.leukres.2010.09.026. Epub 2010 Oct 27.

PMID:
21030078
19.

A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma.

Sánchez-Espiridión B, Montalbán C, López A, Menárguez J, Sabín P, Ruiz-Marcellán C, Lopez A, Ramos R, Rodríguez J, Cánovas A, Camarero C, Canales M, Alves J, Arranz R, Acevedo A, Salar A, Serrano S, Bas A, Moraleda JM, Sánchez-Godoy P, Burgos F, Rayón C, Fresno MF, Laraña JG, García-Cosío M, Santonja C, López JL, Llanos M, Mollejo M, González-Carrero J, Marín A, Forteza J, García-Sanz R, Tomás JF, Morente MM, Piris MA, García JF; Spanish Hodgkin Lymphoma Study Group.

Blood. 2010 Aug 26;116(8):e12-7. doi: 10.1182/blood-2010-02-270009. Epub 2010 May 17.

PMID:
20479282
20.

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.

Piñana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Díez-Martín JL, Vazquez L, Arranz R, Tomás JF, Sampol A, Solano C, Delgado J, Sierra J, Caballero D; GELTAMO Group.

Haematologica. 2010 Jul;95(7):1176-82. doi: 10.3324/haematol.2009.017608. Epub 2010 Jan 27.

21.

Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.

Martínez-López J, Rivero A, Rapado I, Montalbán C, Paz-Carreira J, Canales M, Martínez R, Sánchez-Godoy P, Fernández de Sevilla A, Peñalver FJ, Gonzalez M, Prieto E, Salar A, Burgaleta C, Queizán JA, Peñarrubia MJ, Monteagudo MD, Cabrera C, De la Serna J, Tomás JF.

Leuk Lymphoma. 2009 Aug;50(8):1283-9. doi: 10.1080/10428190903040006.

PMID:
19557622
22.

A TaqMan low-density array to predict outcome in advanced Hodgkin's lymphoma using paraffin-embedded samples.

Sánchez-Espiridión B, Sánchez-Aguilera A, Montalbán C, Martin C, Martinez R, González-Carrero J, Poderos C, Bellas C, Fresno MF, Morante C, Mestre MJ, Mendez M, Mazorra F, Conde E, Castaño A, Sánchez-Godoy P, Tomas JF, Morente MM, Piris MA, García JF; Spanish Hodgkin's Lymphoma Study Group.

Clin Cancer Res. 2009 Feb 15;15(4):1367-75. doi: 10.1158/1078-0432.CCR-08-1119.

23.

Resolution of left and right ventricular thrombosis secondary to hypereosinophilic syndrome (lymphoproliferative variant) with reduced intensity conditioning allogenic stem cell transplantation.

Bergua JM, Prieto-Pliego E, Román-Barberá A, García-Torón J, Gómez-Barrado JJ, Marcos G, López-Gómez L, Tomás JF.

Ann Hematol. 2008 Nov;87(11):937-8. doi: 10.1007/s00277-008-0505-9. Epub 2008 Jun 3. No abstract available.

PMID:
18521601
24.

Antiphospholipid syndrome after non-myeloablative hematopoietic cell transplantation.

Mata R, Llamas P, Román A, Prieto E, López JL, Tomás JF, Subirá D.

Thromb Res. 2008;122(2):283-4. Epub 2008 Feb 20. No abstract available.

PMID:
18068756
25.

Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.

Esteve J, Escoda L, Martín G, Rubio V, Díaz-Mediavilla J, González M, Rivas C, Alvarez C, González San Miguel JD, Brunet S, Tomás JF, Tormo M, Sayas MJ, Sánchez Godoy P, Colomer D, Bolufer P, Sanz MA; Spanish Cooperative Group PETHEMA.

Leukemia. 2007 Mar;21(3):446-52. Epub 2007 Jan 4.

PMID:
17205057
26.

Flow injection potentiometric determination of chlorpromazine.

Sales MG, Tomás JF, Lavandeira SR.

J Pharm Biomed Anal. 2006 Jun 16;41(4):1280-6. Epub 2006 May 2.

PMID:
16650709
27.

Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients.

Pérez-Simón JA, Sureda A, Fernández-Aviles F, Sampol A, Cabrera JR, Caballero D, Martino R, Petit J, Tomás JF, Moraleda JM, Alegre A, Cañizo C, Brunet S, Rosiñol L, Lahuerta J, Díez-Martín JL, León A, García A, Vazquez L, Sierra J, San Miguel JF; Grupo Español de Mieloma.

Leukemia. 2006 Mar;20(3):542-5. No abstract available.

PMID:
16408097
28.

Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético).

Martínez C, Gomez V, Tomás JF, Parody R, Sureda A, Sanz G, Cañizo C, Díez JL, Boqué C; CML Subcommittee of the Spanish Group of Hematopoietic Transplantation (Grupo Español de Trasplante Hemopoyética, GETH).

Bone Marrow Transplant. 2005 Aug;36(4):301-6.

PMID:
15968278
29.

[Massive pulmonary embolism in a patient with an unusual combination of prothrombotic genetic factors].

Belén Santos A, Llamas P, Fernández de Velasco J, Tomás JF.

Med Clin (Barc). 2005 May 21;124(19):758-9. Spanish. No abstract available.

PMID:
15919043
30.

Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients.

Subirá D, Górgolas M, Castañón S, Serrano C, Román A, Rivas F, Tomás JF.

HIV Med. 2005 Jan;6(1):21-6.

31.

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauser A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF, Brand R, Zander AR.

Biol Blood Marrow Transplant. 2004 Oct;10(10):698-708.

32.

Cardiac granulocytic sarcoma (chloroma): in vivo diagnosis with transesophageal echocardiography.

Marcos-Alberca P, Ibáñez B, Rey M, Román A, Rábago R, Orejas M, Tomás JF, Farré J.

J Am Soc Echocardiogr. 2004 Sep;17(9):1000-2.

PMID:
15337968
33.

Diagnostic utility of comparing fibrinogen Clauss and prothrombin time derived method.

Llamas P, Santos AB, Outeiriño J, Soto C, Tomás JF.

Thromb Res. 2004;114(1):73-4. No abstract available.

PMID:
15262488
34.

[Prothrombotic factors in stroke].

Meseguer E, Llamas P, Fernández de Velasco J, García A, Echevarria A, Oña R, Rábano J, Tomas JF, García de Yébenes J.

Neurologia. 2004 Apr;19(3):99-105. Spanish.

PMID:
15088159
35.

Aspergillus fumigatus: a rare cause of vertebral osteomyelitis.

Santos AB, Llamas P, Gadea I, Román A, Subirá D, Prieto E, Tomás JF.

Haematologica. 2004 Apr;89(4):ECR10. No abstract available.

36.

Genotyping and antifungal susceptibility profile of Dipodascus capitatus isolates causing disseminated infection in seven hematological patients of a tertiary hospital.

Gadea I, Cuenca-Estrella M, Prieto E, Diaz-Guerra TM, Garcia-Cia JI, Mellado E, Tomas JF, Rodriguez-Tudela JL.

J Clin Microbiol. 2004 Apr;42(4):1832-6.

37.

Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases.

Martino R, Salavert M, Parody R, Tomás JF, de la Cámara R, Vázquez L, Jarque I, Prieto E, Sastre JL, Gadea I, Pemán J, Sierra J.

Clin Infect Dis. 2004 Feb 1;38(3):335-41. Epub 2004 Jan 14.

PMID:
14727202
38.

Evaluation of thrombophylic states in myeloma patients receiving thalidomide: a reasonable doubt.

Santos AB, Llamas P, Román A, Prieto E, De Oña R, De Velasco JF, Tomás JF.

Br J Haematol. 2003 Jul;122(1):159-60. No abstract available.

PMID:
12823358
39.

Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation.

Pérez-Simón JA, Martino R, Alegre A, Tomás JF, De Leon A, Caballero D, Sureda A, Sierra J, San Miguel JF.

Br J Haematol. 2003 Apr;121(1):104-8.

PMID:
12670339
40.

Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.

Martino R, Caballero MD, de la Serna J, Díez-Martín JL, Urbano-Ispízua A, Tomás JF, Odriozola J, León A, Canals C, San Miguel J, Sierra J.

Bone Marrow Transplant. 2002 Jul;30(2):63-8.

41.

Report of three cases of circulating heparin-like anticoagulants.

Llamas P, Outeiriño J, Espinoza J, Santos AB, Román A, Tomás JF.

Am J Hematol. 2001 Aug;67(4):256-8.

42.

Prothrombin 20210A-associated thrombosis may need concurrency of another prothrombotic factor.

Espinoza J, Llamas P, Fernández de Velasco J, Soto C, Román A, Tomás JF.

Thromb Res. 2001 May 15;102(4):381-3. No abstract available.

PMID:
11421234
43.

Expression of factor VII in the liver of patients with liver disease: correlations with the disease severity and impairment in the hemostasis.

Rodríguez-Iñigo E, Bartolomé J, Quiroga JA, Hedner U, Suárez A, Tomás JF, Manzarbeitia F, Arocena C, Manzano ML, Oliva H, Carreño V.

Blood Coagul Fibrinolysis. 2001 Apr;12(3):193-9.

PMID:
11414633
44.

The irreplaceable image: A giant hepatic mass of myeloid metaplasia in a patient without myelofibrosis.

Gil-Fernández JJ, Martínez-Chamorro C, Tomás JF.

Haematologica. 2001 Apr;86(4):445. No abstract available.

45.

ProC global: an automated screening test for factor V Leiden and prothrombin mutation 20210 G to A detection.

Sillero PL, Fernández de Velasco J, Loscertales J, Espinoza J, Soto C, Tomás JF.

Thromb Res. 2001 Feb 1;101(3):215-6. No abstract available.

PMID:
11291388
46.

Atypical chronic graft-versus-host disease following interferon therapy for chronic myeloid leukaemia relapsing after allogeneic BMT.

Serrano J, Prieto E, Mazarbeitia F, Román A, Llamas P, Tomás JF.

Bone Marrow Transplant. 2001 Jan;27(1):85-7.

47.

Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients.

Tomás JF, Pinilla I, García-Buey ML, García A, Figuera A, Gómez-García de Soria VGG, Moreno R, Fernández-Rañada JM.

Bone Marrow Transplant. 2000 Sep;26(6):649-55.

48.

Abnormal bleeding in a patient with chronic lymphocytic leukemia and acute hepatitis due to a circulating heparin-like anticoagulant.

Llamas P, Prieto E, Román A, Espinoza J, Soto C, Tomás JF.

Haematologica. 2000 Jul;85(7):777-8. No abstract available.

49.

Measurement of the procoagulant activity of factor VII in patients with liver cirrhosis and normal prothrombin activity: evaluation of the bleeding risk.

Manzano ML, Arocena C, Tomás JF, Hedner U, Quiroga JA, Carreño V.

Blood Coagul Fibrinolysis. 2000 Apr;11 Suppl 1:S95-9.

PMID:
10850572
50.

Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético.

Carreras E, Tomás JF, Sanz G, Iriondo A, Boqué C, López J, Cabrera R, Sureda A, de Soria VG, Sierra J, Sanz MA, Torres A.

Haematologica. 2000 May;85(5):530-8.

Supplemental Content

Loading ...
Support Center